101 related articles for article (PubMed ID: 17593631)
1. Investigation of the role of p53 in chemotherapy resistance of lung cancer cell lines.
Breen L; Heenan M; Amberger-Murphy V; Clynes M
Anticancer Res; 2007; 27(3A):1361-4. PubMed ID: 17593631
[TBL] [Abstract][Full Text] [Related]
2. [Functional status of p53 and chemosensitivity of colon cancer cell lines].
Jia L; Yu L; Zhu S
Zhonghua Zhong Liu Za Zhi; 2000 Sep; 22(5):389-90. PubMed ID: 11778275
[TBL] [Abstract][Full Text] [Related]
3. [The combination of recombinant rAd-p53 and adriamycin for management of primary drug resistance in chemotherapy of lung squamous cell cancer].
Du CH; Wu Z; Xu J
Zhonghua Jie He He Hu Xi Za Zhi; 2006 Sep; 29(9):622-4. PubMed ID: 17129471
[TBL] [Abstract][Full Text] [Related]
4. Cooperative effect of adenoviral p53 gene therapy and standard chemotherapy in ovarian cancer cells independent of the endogenous p53 status.
Quist SR; Wang-Gohrke S; Köhler T; Kreienberg R; Runnebaum IB
Cancer Gene Ther; 2004 Aug; 11(8):547-54. PubMed ID: 15153938
[TBL] [Abstract][Full Text] [Related]
5. Increasing p53 protein sensitizes non-small cell lung cancer to paclitaxel and cisplatin in vitro.
Guntur VP; Waldrep JC; Guo JJ; Selting K; Dhand R
Anticancer Res; 2010 Sep; 30(9):3557-64. PubMed ID: 20944137
[TBL] [Abstract][Full Text] [Related]
6. Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line.
Chan KT; Lung ML
Cancer Chemother Pharmacol; 2004 Jun; 53(6):519-26. PubMed ID: 15004724
[TBL] [Abstract][Full Text] [Related]
7. Drug resistance in malignant rhabdoid tumor cell lines.
Rosson GB; Vincent TS; Oswald BW; Wright CF
Cancer Chemother Pharmacol; 2002 Feb; 49(2):142-8. PubMed ID: 11862428
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel enhanced radiation sensitization for the suppression of human prostate cancer tumor growth via a p53 independent pathway.
Zhang AL; Russell PJ; Knittel T; Milross C
Prostate; 2007 Nov; 67(15):1630-40. PubMed ID: 17823933
[TBL] [Abstract][Full Text] [Related]
9. Influence of p53 expression on sensitivity of cancer cells to bleomycin.
Lee YS; Yoon S; Park MS; Kim JH; Lee JH; Song CW
J Biochem Mol Toxicol; 2010; 24(4):260-9. PubMed ID: 20135637
[TBL] [Abstract][Full Text] [Related]
10. [Roles of mutant p53 gene in malignant phenotypes and resistance to drugs in anti-7,8-dihydrodiol-9,10-epoxide benzo(a)pyrene-induced lung cancer cells].
Du CH; Xu J; Zhong NS
Zhonghua Jie He He Hu Xi Za Zhi; 2005 Mar; 28(3):176-9. PubMed ID: 15854413
[TBL] [Abstract][Full Text] [Related]
11. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
[TBL] [Abstract][Full Text] [Related]
12. p53 status is a major determinant of effects of decreasing peroxiredoxin I expression on tumor growth and response of lung cancer cells to treatment.
Chen MF; Chen WC; Wu CT; Lin PY; Shau H; Liao SK; Yang CT; Lee KD
Int J Radiat Oncol Biol Phys; 2006 Dec; 66(5):1461-72. PubMed ID: 17084559
[TBL] [Abstract][Full Text] [Related]
13. p53 Cooperates berberine-induced growth inhibition and apoptosis of non-small cell human lung cancer cells in vitro and tumor xenograft growth in vivo.
Katiyar SK; Meeran SM; Katiyar N; Akhtar S
Mol Carcinog; 2009 Jan; 48(1):24-37. PubMed ID: 18459128
[TBL] [Abstract][Full Text] [Related]
14. Cellular models of drug- and radiation-resistant small cell lung cancer.
Davey RA; Locke VL; Henness S; Harvie RM; Davey MW
Anticancer Res; 2004; 24(2A):465-71. PubMed ID: 15152945
[TBL] [Abstract][Full Text] [Related]
15. Abnormal stability of wild-type p53 protein in a human lung carcinoma cell line.
Yamauchi M; Suzuki K; Kodama S; Watanabe M
Biochem Biophys Res Commun; 2005 May; 330(2):483-8. PubMed ID: 15796908
[TBL] [Abstract][Full Text] [Related]
16. The dual role of mutant p53 protein in chemosensitivity of human cancers.
Mueller H; Eppenberger U
Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
[TBL] [Abstract][Full Text] [Related]
17. Accumulation, platinum-DNA adduct formation and cytotoxicity of cisplatin, oxaliplatin and satraplatin in sensitive and resistant human osteosarcoma cell lines, characterized by p53 wild-type status.
Martelli L; Di Mario F; Botti P; Ragazzi E; Martelli M; Kelland L
Biochem Pharmacol; 2007 Jun; 74(1):20-7. PubMed ID: 17466278
[TBL] [Abstract][Full Text] [Related]
18. p53 dependent and independent sensitivity to oxaliplatin of colon cancer cells.
Toscano F; Parmentier B; Fajoui ZE; Estornes Y; Chayvialle JA; Saurin JC; Abello J
Biochem Pharmacol; 2007 Aug; 74(3):392-406. PubMed ID: 17559811
[TBL] [Abstract][Full Text] [Related]
19. p53 determines multidrug sensitivity of childhood neuroblastoma.
Xue C; Haber M; Flemming C; Marshall GM; Lock RB; MacKenzie KL; Gurova KV; Norris MD; Gudkov AV
Cancer Res; 2007 Nov; 67(21):10351-60. PubMed ID: 17974978
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/Taxol sensitivity in human renal cell carcinoma is not determined by the p53 status.
Reinecke P; Kalinski T; Mahotka C; Schmitz M; Déjosez M; Gabbert HE; Gerharz CD
Cancer Lett; 2005 May; 222(2):165-71. PubMed ID: 15863265
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
